Journal articles on the topic 'BRCA2'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'BRCA2.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Friedlander, Michael, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Alla Sergeevna Lisyanskaya, et al. "Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 5551. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5551.
Full textZhang, Yinuo. "BRCA1, BRCA2 and primary ovarian insufficiency." E3S Web of Conferences 165 (2020): 05009. http://dx.doi.org/10.1051/e3sconf/202016505009.
Full textWang, Aifen, Robert W. Holloway, Lijuan Cui, Yan Sun, and Zihan Zhao. "Association betweenBRCA1 and BRCA2 mutations and prognosis in women with endometrial carcinoma." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e17115-e17115. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e17115.
Full textPonce, Jordi, Sergi Fernandez-Gonzalez, Iris Calvo, Maite Climent, Judith Peñafiel, Lidia Feliubadaló, Alex Teulé, et al. "Assessment of ovarian reserve and reproductive outcomes in BRCA1 or BRCA2 mutation carriers." International Journal of Gynecologic Cancer 30, no. 1 (November 27, 2019): 83–88. http://dx.doi.org/10.1136/ijgc-2019-000626.
Full textLabidi-Galy, Sana Intidhar, Manuel Rodrigues, Jose L. Sandoval, Jean Emmanuel Kurtz, Florian Heitz, Anna Maria Mosconi, Ignacio Romero, et al. "Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 5571. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5571.
Full textLabidi-Galy, Sana Intidhar, Manuel Rodrigues, Jose L. Sandoval, Jean Emmanuel Kurtz, Florian Heitz, Anna Maria Mosconi, Ignacio Romero, et al. "Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 5571. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5571.
Full textRichters, Lisa Katharina, Philip C. Schouten, Stefan Kommoss, Jan Hauke, Alexander Burges, Dimo Dietrich, Ahmed El-Balat, et al. "BRCA-like classification in ovarian cancer: Results from the AGO-TR1-trial." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 5546. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5546.
Full textArun, Banu, Angelica Gutierrez Barrera, Rachel M. Layman, Stephen K. Gruschkus, Isabelle Bedrosian, Constance T. Albarracin, Carlos Hernando Barcenas, Vicente Valero, Jennifer Keating Litton, and Debu Tripathy. "Outcome of patients with breast cancer and a germline BRCA mutation in a prospective cohort." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 1544. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1544.
Full textSy, Shirley M. H., Michael S. Y. Huen, and Junjie Chen. "PALB2 is an integral component of the BRCA complex required for homologous recombination repair." Proceedings of the National Academy of Sciences 106, no. 17 (April 15, 2009): 7155–60. http://dx.doi.org/10.1073/pnas.0811159106.
Full textShatavi, Seerin Viviane, Lindsay Dohany, Mohammad Muhsin Chisti, Ishmael A. Jaiyesimi, and Dana Zakalik. "Unique genetic characteristics of BRCA mutation carriers in a cohort of Arab American women." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 1541. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.1541.
Full textKeung, Yi-Kong, Adriana Hu, Annie Yeung, Amy Chan, and Eddie Hu. "Higher prevalence of BRCA2 mutations among Chinese breast cancer patients in a community oncology clinic." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e12017-e12017. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e12017.
Full textKauff, Noah D., Susan M. Domchek, Tara M. Friebel, Mark E. Robson, Johanna Lee, Judy E. Garber, Claudine Isaacs, et al. "Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study." Journal of Clinical Oncology 26, no. 8 (March 10, 2008): 1331–37. http://dx.doi.org/10.1200/jco.2007.13.9626.
Full textPanda, Anshuman, Mark N. Stein, Gregory Riedlinger, Gyan Bhanot, and Shridar Ganesan. "Role for immune checkpoint blockade in BRCA2-mutant prostate cancer." Journal of Clinical Oncology 37, no. 8_suppl (March 10, 2019): 59. http://dx.doi.org/10.1200/jco.2019.37.8_suppl.59.
Full textBracci, Ciarapica, Zabaleta, Tartaglione, Pirozzi, Giuliani, Piva, et al. "BRCA1 and BRCA2 Gene Expression: Diurnal Variability and Influence of Shift Work." Cancers 11, no. 8 (August 9, 2019): 1146. http://dx.doi.org/10.3390/cancers11081146.
Full textChahla, Elie, Antonio Cheesman, Suzanne M. Mahon, Robert W. Garrett, Ben P. Bradenham, Theresa L. Schwartz, Louay Omran, Jason R. Taylor, and Samer Alkaade. "Frequency and Significance of Abnormal Pancreatic Imaging in Patients with BRCA1 and BRCA2 Genetic Mutations." Scientifica 2016 (2016): 1–6. http://dx.doi.org/10.1155/2016/5619358.
Full textFerrone, Cristina R., Douglas A. Levine, Laura H. Tang, Peter J. Allen, William Jarnagin, Murray F. Brennan, Kenneth Offit, and Mark E. Robson. "BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma." Journal of Clinical Oncology 27, no. 3 (January 20, 2009): 433–38. http://dx.doi.org/10.1200/jco.2008.18.5546.
Full textReisinger, Raquel, Sergiusz Wesolowski, Umang Swami, Pedro C. Barata, Edgar Javier Hernandez, Roberto Nussenzveig, Gordon Lemmon, et al. "Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA)." Journal of Clinical Oncology 39, no. 6_suppl (February 20, 2021): 162. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.162.
Full textFaermann, Renata, Eitan Friedman, Orit Kaidar-Person, Jonathan Weidenfeld, Malka Brodsky, Anat Shalmon, Osnat Halshtok Neiman, et al. "Ductal Carcinoma In Situ (DCIS) Diagnosed by MRI-Guided Biopsy among BRCA1/BRCA2 Mutation Carriers." Breast Journal 2022 (October 27, 2022): 1–7. http://dx.doi.org/10.1155/2022/4317693.
Full textFoglietta, Jennifer, Vienna Ludovini, Fortunato Bianconi, Lorenza Pistola, Maria Sole Reda, Antonella Al-Refaie, Francesca Romana Tofanetti, et al. "Prevalence and Spectrum of BRCA Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study." Genes 11, no. 8 (August 12, 2020): 925. http://dx.doi.org/10.3390/genes11080925.
Full textBisgin, Atil, Ibrahim Boga, Ozge Sonmezler, Cem Mujde, Abdullah Hanta, and Sevcan Tug Bozdogan. "Meta-analysis and single-center experience on the comprehensive genomic characterization and landscape of BRCA1 and BRCA2 in Turkey." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e13611-e13611. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e13611.
Full textKiechle, M. "Hereditäres Mammakarzinom: BRCA1, BRCA2 und BRCA3." Senologie - Zeitschrift für Mammadiagnostik und -therapie 8, no. 02 (June 2011): 103. http://dx.doi.org/10.1055/s-0031-1271518.
Full textKwong, A., L. Wong, C. Wong, F. Law, E. Tang, W. Chan, E. S. Ma, J. M. Ford, and D. W. West. "Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e22226-e22226. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e22226.
Full textZajchowski, Deborah A., Hugh Salamon, and Ken D. Yamaguchi. "Proliferation pathway aberration frequencies in BRCA1- and BRCA2-mutated ovarian cancers." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 5074. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.5074.
Full textLi, Jiaheng, Bojin Zhao, Teng Huang, Zixin Qin, and San Ming Wang. "Human BRCA pathogenic variants were originated during recent human history." Life Science Alliance 5, no. 5 (February 14, 2022): e202101263. http://dx.doi.org/10.26508/lsa.202101263.
Full textTun, N. M., G. M. Villani, and K. Ong. "Risk of having BRCA mutations in women with triple-negative breast cancer: A systematic review and meta-analysis." Journal of Clinical Oncology 29, no. 27_suppl (September 20, 2011): 160. http://dx.doi.org/10.1200/jco.2011.29.27_suppl.160.
Full textNovikova, EI, EA Kudinova, VK Bozhenko, and VA Solodkiy. "Characteristics of BRCA-associated breast cancer in the population of the Russian Federation." Features of HIV and SARS-CoV-2 coinfection in a pandemic, no. 2021(1) (February 2021): 24–29. http://dx.doi.org/10.24075/brsmu.2021.006.
Full textWen, Lu, Xiuxiu Li, Junping Shi, Shuo Zhang, Rui Wang, Ming Yao, and Jun Guo. "Allele-specific expression mediates primary resistance to poly (ADP-ribose) polymerase inhibitor therapy in a case of BRCA1/2 double-germline mutant gastric cancer." Journal of International Medical Research 48, no. 3 (November 27, 2019): 030006051988622. http://dx.doi.org/10.1177/0300060519886226.
Full textRhiem, K., C. Fischer, K. Bosse, B. Wappenschmidt, and R. K. Schmutzler. "Increased risk of cervical cancer in high-risk families with and without mutations in the BRCA1 and BRCA2 genes." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 5588. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.5588.
Full textMcNevin, Ciara S., Karen Cadoo, Anne-Marie Baird, Pierre Murchan, Orla Sheils, Ray McDermott, and Stephen Finn. "Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer." Cancers 13, no. 22 (November 14, 2021): 5697. http://dx.doi.org/10.3390/cancers13225697.
Full textChoi, Doo Ho, Min Hyuk Lee, Allen E. Bale, Darryl Carter, and Bruce G. Haffty. "Incidence of BRCA1 and BRCA2 Mutations in Young Korean Breast Cancer Patients." Journal of Clinical Oncology 22, no. 9 (May 1, 2004): 1638–45. http://dx.doi.org/10.1200/jco.2004.04.179.
Full textCastro, Elena, David Olmos, Chee Leng Goh, Ed Saunders, Daniel Leongamornlert, Malgorzata Tymrakiewicz, Elizabeth Bancroft, et al. "Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer." Journal of Clinical Oncology 31, no. 6_suppl (February 20, 2013): 29. http://dx.doi.org/10.1200/jco.2013.31.6_suppl.29.
Full textJoó, József Gábor, Szabolcs Ládi, B. Zsolt Nagy, and Zoltán Langmár. "Management of hereditary ovarian cancer." Orvosi Hetilap 152, no. 40 (October 2011): 1596–608. http://dx.doi.org/10.1556/oh.2011.29218.
Full textPal, Tuya, Deborah Cragun, Xuefeng Wang, Sean J. Yoder, Tania MESA, Marilin Rosa, Ann Tezak, Anne Weidner, Susan Thomas Vadaparampil, and Catherine Phelan. "Characterization of germline and tumor genomic profile in unselected young black breast cancer patients." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e13090-e13090. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e13090.
Full textVidra, Radu, Tudor Eliade Ciuleanu, Adina Nemeș, Oana Pascu, Ana Maria Heroiu, Nicoleta Antone, Andreea Iulia Vidrean, et al. "Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients." International Journal of Environmental Research and Public Health 19, no. 7 (April 4, 2022): 4314. http://dx.doi.org/10.3390/ijerph19074314.
Full textSahnane, Nora, Ileana Carnevali, Giorgio Formenti, Jvan Casarin, Sofia Facchi, Raffaella Bombelli, Eleonora Di Lauro, et al. "BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor." International Journal of Molecular Sciences 21, no. 24 (December 19, 2020): 9708. http://dx.doi.org/10.3390/ijms21249708.
Full textShao, Changxia, Michael S. Chang, Fred C. Lam, Andrew R. Marley, Huilin Tang, Yiqing Song, Chelsey Miller, et al. "A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer." Journal of Oncology 2022 (July 20, 2022): 1–12. http://dx.doi.org/10.1155/2022/5830475.
Full textLattimore, Vanessa, John Pearson, Arthur Morley-Bunker, kConFab Investigators, Amanda Spurdle, Bridget Robinson, Margaret Currie, and Logan Walker. "Quantifying BRCA1 and BRCA2 mRNA Isoform Expression Levels in Single Cells." International Journal of Molecular Sciences 20, no. 3 (February 6, 2019): 693. http://dx.doi.org/10.3390/ijms20030693.
Full textCaleca, Laura, Mara Colombo, Thomas van Overeem Hansen, Conxi Lázaro, Siranoush Manoukian, Michael T. Parsons, Amanda B. Spurdle, and Paolo Radice. "GFP-Fragment Reassembly Screens for the Functional Characterization of Variants of Uncertain Significance in Protein Interaction Domains of the BRCA1 and BRCA2 Genes." Cancers 11, no. 2 (January 28, 2019): 151. http://dx.doi.org/10.3390/cancers11020151.
Full textSchwartz, Zachary Phillip, Mae Zakhour, Andrew John Li, Christine S. Walsh, Bj Rimel, Monica Alvarado, Scott E. Lentz, and Ilana Cass. "Comparison of risk-reducing surgery in women with BRCA and non-BRCA ovarian cancer susceptibility genes." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 1547. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1547.
Full textMitamura, Takashi, Masayuki Sekine, Masami Arai, Yuka Shibata, Momoko Kato, Shiro Yokoyama, Hiroko Yamashita, et al. "Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome." Japanese Journal of Clinical Oncology 50, no. 12 (July 17, 2020): 1380–85. http://dx.doi.org/10.1093/jjco/hyaa124.
Full textGraeser, Monika K., Christoph Engel, Kerstin Rhiem, Dorothea Gadzicki, Ulrich Bick, Karin Kast, Ursula G. Froster, et al. "Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers." Journal of Clinical Oncology 27, no. 35 (December 10, 2009): 5887–92. http://dx.doi.org/10.1200/jco.2008.19.9430.
Full textCastro, Elena, David Olmos, Chee Leng Goh, Ed Saunders, Daniel Leongamornlert, Malgorzata Tymrakiewicz, Elizabeth Bancroft, et al. "BRCA carrier status as an independent prognostic factor associated with earlier biochemical relapse in local prostate cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 1545. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.1545.
Full textLiu, Ying L., Julia Lindsay Boland, Karen Anne Cadoo, Claire Frances Friedman, Jason A. Konner, Roisin Eilish O'Cearbhaill, Carol Aghajanian, and Dmitriy Zamarin. "Response to immune checkpoint inhibition and survival in BRCA-associated recurrent ovarian cancer." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 2615. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.2615.
Full textTabaliuk, Y. O., L. A. Rybchenko, B. T. Klimuk, and S. V. Klymenko. "Screening for mutations in BRCA1 and BRCA2 genes and related perspectives for the healthcare system." Visnik ukrains'kogo tovaristva genetikiv i selekcioneriv 18, no. 1-2 (January 29, 2021): 44–57. http://dx.doi.org/10.7124/visnyk.utgis.18.1-2.1354.
Full textDufloth, Rozany Mucha, Sílvia Carvalho, Juliana Karina Heinrich, Júlia Yoriko Shinzato, César Cabello dos Santos, Luiz Carlos Zeferino, and Fernando Schmitt. "Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history." Sao Paulo Medical Journal 123, no. 4 (2005): 192–97. http://dx.doi.org/10.1590/s1516-31802005000400007.
Full textAyoub, Jean-Pierre, Hans Wildiers, Michael Friedlander, Banu K. Arun, Hyo S. Han, Shannon Puhalla, Yaroslav Shparyk, et al. "Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial." Therapeutic Advances in Medical Oncology 13 (January 2021): 175883592110596. http://dx.doi.org/10.1177/17588359211059601.
Full textDall'era, Marc, Christopher P. Evans, Chong-Xian Pan, Mamta Parikh, Primo Lara, and John McPherson. "Are prostate cancer patients with BRCA1 and BRCA2 mutations safe for active surveillance?" Journal of Clinical Oncology 37, no. 7_suppl (March 1, 2019): 19. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.19.
Full textOh, Mok, Ali McBride, Seongseok Yun, Sandipan Bhattacharjee, Marion Slack, Joanne M. Jeter, and Ivo Abraham. "BRCA1 and BRCA2 gene mutations and colorectal cancer risk: Systematic review and meta-analysis." Journal of Clinical Oncology 36, no. 4_suppl (February 1, 2018): 605. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.605.
Full textShweash, Muhannad, Saddam Jumaa Naseer, Maisam Khider Al-anii, and Thulfiqar Fawwaz Mutar. "A MOLECULAR-BASED APPROACH TO INVESTIGATE BREAST CANCER 1 AND BREAST CANCER 2 STATUS IN OVARIAN CANCER AMONG IRAQI WOMEN." Asian Journal of Pharmaceutical and Clinical Research 11, no. 7 (July 7, 2018): 199. http://dx.doi.org/10.22159/ajpcr.2018.v11i7.25217.
Full textTrombetta, Mark, Katherine Kotinsley, and Thomas B. Julian. "Breast conservation surgery and radiation for a patient with synchronous primary breast cancers and BRCA1/BRCA2 positivity: is mastectomy required?" Journal of Radiotherapy in Practice 11, no. 1 (March 18, 2011): 62–65. http://dx.doi.org/10.1017/s1460396911000021.
Full text